Systematic Pharmacogenomics Analysis of a Malay Whole Genome: Proof of Concept for Personalized Medicine

Background:With a higher throughput and lower cost in sequencing, second generation sequencing technology has immense potential for translation into clinical practice and in the realization of pharmacogenomics based patient care. The systematic analysis of whole genome sequences to assess patient to...

Full description

Bibliographic Details
Main Authors: Adam, A. (Author), Ahmed, A.Z (Author), Hamzah, A.S (Author), Hatta, F.H.M (Author), Hoh, B.P (Author), Ismail, M.I (Author), Ismet, R.I (Author), Janor, R.M (Author), Joshi, K. (Author), Lee, L.S (Author), Pasha, A. (Author), Patowary, A. (Author), Salleh, M.Z (Author), Scaria, V. (Author), Sivasubbu, S. (Author), Teh, L.K (Author), Yusoff, K. (Author)
Format: Article
Language:English
Subjects:
Online Access:View Fulltext in Publisher
View in Scopus
LEADER 04712nam a2200877Ia 4500
001 10.1371-journal.pone.0071554
008 220112s2013 CNT 000 0 und d
020 |a 19326203 (ISSN) 
245 1 0 |a Systematic Pharmacogenomics Analysis of a Malay Whole Genome: Proof of Concept for Personalized Medicine 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1371/journal.pone.0071554 
856 |z View in Scopus  |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882970247&doi=10.1371%2fjournal.pone.0071554&partnerID=40&md5=4d8919f0ff3d059a571a19587cee73b7 
520 3 |a Background:With a higher throughput and lower cost in sequencing, second generation sequencing technology has immense potential for translation into clinical practice and in the realization of pharmacogenomics based patient care. The systematic analysis of whole genome sequences to assess patient to patient variability in pharmacokinetics and pharmacodynamics responses towards drugs would be the next step in future medicine in line with the vision of personalizing medicine.Methods:Genomic DNA obtained from a 55 years old, self-declared healthy, anonymous male of Malay descent was sequenced. The subject's mother died of lung cancer and the father had a history of schizophrenia and deceased at the age of 65 years old. A systematic, intuitive computational workflow/pipeline integrating custom algorithm in tandem with large datasets of variant annotations and gene functions for genetic variations with pharmacogenomics impact was developed. A comprehensive pathway map of drug transport, metabolism and action was used as a template to map non-synonymous variations with potential functional consequences.Principal Findings:Over 3 million known variations and 100,898 novel variations in the Malay genome were identified. Further in-depth pharmacogenetics analysis revealed a total of 607 unique variants in 563 proteins, with the eventual identification of 4 drug transport genes, 2 drug metabolizing enzyme genes and 33 target genes harboring deleterious SNVs involved in pharmacological pathways, which could have a potential role in clinical settings.Conclusions:The current study successfully unravels the potential of personal genome sequencing in understanding the functionally relevant variations with potential influence on drug transport, metabolism and differential therapeutic outcomes. These will be essential for realizing personalized medicine through the use of comprehensive computational pipeline for systematic data mining and analysis. © 2013 Salleh et al. 
650 0 4 |a adult 
650 0 4 |a article 
650 0 4 |a Asian Continental Ancestry Group 
650 0 4 |a Biological Markers 
650 0 4 |a Chromosome Mapping 
650 0 4 |a Computational Biology 
650 0 4 |a controlled study 
650 0 4 |a disease marker 
650 0 4 |a drug response 
650 0 4 |a ethnic group 
650 0 4 |a family history 
650 0 4 |a Female 
650 0 4 |a gene frequency 
650 0 4 |a gene function 
650 0 4 |a gene identification 
650 0 4 |a gene mapping 
650 0 4 |a genetic association 
650 0 4 |a genetic marker 
650 0 4 |a Genetic Predisposition to Disease 
650 0 4 |a genetic variability 
650 0 4 |a genome analysis 
650 0 4 |a Genome, Human 
650 0 4 |a Genome-Wide Association Study 
650 0 4 |a genomic DNA 
650 0 4 |a Genomics 
650 0 4 |a High-Throughput Nucleotide Sequencing 
650 0 4 |a human 
650 0 4 |a Humans 
650 0 4 |a Individualized Medicine 
650 0 4 |a Malay 
650 0 4 |a Malaysia 
650 0 4 |a male 
650 0 4 |a Male 
650 0 4 |a Middle Aged 
650 0 4 |a outcome assessment 
650 0 4 |a patient assessment 
650 0 4 |a personalized medicine 
650 0 4 |a Pharmacogenetics 
650 0 4 |a pharmacogenomics 
650 0 4 |a Polymorphism, Single Nucleotide 
650 0 4 |a Quantitative Trait Loci 
650 0 4 |a Quantitative Trait, Heritable 
650 0 4 |a sequence alignment 
650 0 4 |a sequence analysis 
650 0 4 |a signal transduction 
650 0 4 |a single nucleotide polymorphism 
700 1 0 |a Adam, A.  |e author 
700 1 0 |a Ahmed, A.Z.  |e author 
700 1 0 |a Hamzah, A.S.  |e author 
700 1 0 |a Hatta, F.H.M.  |e author 
700 1 0 |a Hoh, B.P.  |e author 
700 1 0 |a Ismail, M.I.  |e author 
700 1 0 |a Ismet, R.I.  |e author 
700 1 0 |a Janor, R.M.  |e author 
700 1 0 |a Joshi, K.  |e author 
700 1 0 |a Lee, L.S.  |e author 
700 1 0 |a Pasha, A.  |e author 
700 1 0 |a Patowary, A.  |e author 
700 1 0 |a Salleh, M.Z.  |e author 
700 1 0 |a Scaria, V.  |e author 
700 1 0 |a Sivasubbu, S.  |e author 
700 1 0 |a Teh, L.K.  |e author 
700 1 0 |a Yusoff, K.  |e author 
773 |t PLoS ONE